Recombinant human PD-1 antibody herpes simplex virus

重组人PD-1抗体单纯疱疹病毒

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant human PD-1 antibody herpes simplex virus
Drug Alias NameN/A
ClassificationBiologics > Oncolytic virus
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsBrain metastasesSolid tumoursUrinary Bladder Neoplasms +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesXiamen UniversityYangsheng Tang Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesXiamen UniversityYangsheng Tang Co LtdZhejiang Yangshengtang Biological Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsBrain metastasesSolid tumoursUrinary Bladder Neoplasms +[12] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A